RESUMO
BACKGROUND: In clinical trials, canarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV-specific cytotoxic T lymphocyte (CTL) responses in some but not all healthy uninfected adults.Methods. A clinical trial was conducted to examine whether the vaccine vCP1452 would elicit a greater HIV-specific CTL response when given at a dose of 10(8.0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants). RESULTS: Two weeks after the last vaccination in a series, HIV-specific CTL responses were not significantly different when measured by either chromium-release assay (8% and 16% in the high- and regular-dose recipients, respectively) or interferon- gamma ELISpot assay (8% and 15% in the high- and regular-dose recipients, respectively); moreover, recipients of the higher dose had greater local and systemic reactions (P<.001). CONCLUSIONS: High reactogenicity associated with an increased dose of vCP1452 negates the need for further evaluation of this strategy to boost the frequency of HIV-specific CTL response in seronegative human subjects. Development of highly immunogenic canarypox vectors requires further work to optimize vector and insert design, as well as novel ways to increase dosage and to reduce reactogenicity.
Assuntos
Vacinas contra a AIDS/administração & dosagem , Soronegatividade para HIV/imunologia , Proteínas Recombinantes/imunologia , Linfócitos T Citotóxicos/imunologia , Vacinas Sintéticas/administração & dosagem , Proteínas Virais/metabolismo , Vacinas contra a AIDS/genética , Vacinas contra a AIDS/imunologia , Método Duplo-Cego , Feminino , Anticorpos Anti-HIV/sangue , HIV-1/imunologia , Humanos , Interferon gama/metabolismo , Masculino , Proteínas Recombinantes/metabolismo , Resultado do Tratamento , Vacinação , Vacinas Sintéticas/imunologia , Proteínas Virais/genética , Proteínas Virais/imunologiaRESUMO
PURPOSE/OBJECTIVES: To explore the use of virtual reality as a distraction intervention to relieve symptom distress in women receiving chemotherapy for breast cancer. DESIGN: Crossover study. SETTING: The outpatient clinic of a midwestern comprehensive cancer center. SAMPLE: 20 women 18-55 years of age. METHODS: Using a crossover design, 20 subjects served as their own controls. For two matched chemotherapy treatments, one pretest and two post-test measures were employed. Participants were assigned randomly to receive the virtual reality distraction intervention during one chemotherapy treatment and received no distraction intervention (control condition) during an alternate chemotherapy treatment. An open-ended questionnaire elicited each subject's evaluation of the intervention. MAIN RESEARCH VARIABLES: Symptom distress, fatigue, anxiety. FINDINGS: Significant decreases in symptom distress and fatigue occurred immediately following chemotherapy treatments when women used the virtual reality intervention. CONCLUSIONS: The distraction intervention decreased symptom distress, was well received, and was easy to implement in the clinical setting. IMPLICATIONS FOR NURSING: Nursing interventions to manage chemotherapy-related symptom distress can improve patient quality of life and increase chances for survival by reducing treatment-related symptom distress and enhancing patients' ability to adhere to treatment regimens and cope with their disease.
Assuntos
Adaptação Psicológica , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ansiedade/prevenção & controle , Recursos Audiovisuais , Neoplasias da Mama/tratamento farmacológico , Fadiga/prevenção & controle , Náusea/prevenção & controle , Interface Usuário-Computador , Adolescente , Adulto , Anorexia/induzido quimicamente , Anorexia/prevenção & controle , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ansiedade/induzido quimicamente , Atenção , Neoplasias da Mama/psicologia , Estudos Cross-Over , Fadiga/induzido quimicamente , Humanos , Pessoa de Meia-Idade , Modelos Psicológicos , Náusea/induzido quimicamente , Dor/induzido quimicamente , Dor/prevenção & controle , Aceitação pelo Paciente de Cuidados de Saúde , Transtornos Respiratórios/induzido quimicamente , Transtornos Respiratórios/prevenção & controle , Índice de Gravidade de Doença , Transtornos do Sono-Vigília/induzido quimicamente , Transtornos do Sono-Vigília/prevenção & controle , Inquéritos e Questionários , Resultado do TratamentoRESUMO
The contribution of the factor Va C1 domain (fVa-C1) to assembly of the prothrombinase complex has not been previously investigated. The homologous fVa-C2 domain contains a binding site for phosphatidylserine (PS) that includes the indole moieties of Trp(2063)/Trp(2064) at the apex of spike-1. In order to investigate the structure and function of fVa-C1 a molecular model was constructed based on the structure of fVa-C2. The aromatic and hydrophobic side chains of Tyr (1956) /Leu (1957) in fVa-C1 are located at the predicted apex of spike-3. Exposed charged and hydrophobic residues in fVa-C1 were changed to alanine in clusters of 1-3 mutations per construct. The resultant 20 mutants were expressed in COS cells and screened for binding to immobilized PS and prothrombinase activity on phospholipid vesicles containing either 25% or 5% PS. Two mutants, (Y1956,L1957)A, and (R2023,R2027)A showed both decreased binding to immobilized PS and a selective decrease in prothrombinase activity on membranes containing 5% PS. The interaction of purified (Y1956,L1957)A with phospholipid vesicles was studied using fluorescence resonance energy transfer and prothrombinase assays. The affinity of (Y1956,L1957)A binding to 25% PS membranes was reduced 12-fold compared to rHFVa. Prothrombin activation in the presence of (Y1956,L1957)A was markedly impaired on phos-pholipid vesicles containing 10% or less PS. We conclude that solvent exposed hydrophobic and aromatic amino acids in both fVa-C1 and fVa-C2 contribute to the interaction of factor V with PS membranes.